Reimbursement

The American Hospital Association and individual hospitals have initiated new principles for ensuring good stewardship of the 340B drug program.

According to evidence presented at trial, from approximately December 2011 to August 2015, Ramirez, Shepherd and Nwoko conspired and schemed to defraud Medicare out of payments for medical services.

One in 5 test results showed potentially dangerous concurrent use of opioids and benzodiazepines in 2017.

With Hurricane Florence about to strike, pharmacies must take extra steps to maintain services for patients in need of lifesaving medications.

Spending for the 10 most expensive brand name combination drugs could have been reduced by an estimated $2.7 billion between 2011 and 2016 if lower-cost generics had been prescribed, according to researchers.

Jesse C. Dresser, JD, Partner, Frier & Levitt, LLC, speaks about pharmacy benefit manager-owned specialty pharmacies and how they can impact independent specialty pharmacies.

An evolving pharmacy practice started with the the owners' vision, and worked backwards to become a reality.

health care reimbursements for medications in the United States are not consistently aligned with their value or net health benefits, according to a new study.

Jesse C. Dresser, JD, Partner, Frier & Levitt, LLC, speaks about the regulation of pharmacy benefit managers and how it can impact specialty pharmacy operations.

Ali McBride, PharmD, MS, BCPS, BCOP, explains what strategies can help ensure patients are adherent to oral chemotherapy regimens.

Survey authors identified an unmet need for clinician engagement regarding financial concerns after breast cancer diagnosis.

Jesse C. Dresser, JD, Partner, Frier & Levitt, LLC, discusses laws that help specialty pharmacies access restricted pharmacy networks.

Achilles Alon, PharmD, RPh, Director of Specialty Pharmacy, Co-owner of ACE-Rx Specialty Pharmacy, discusses the importance of pharmacists when treating patients with specialty medications.

Current definitions attempting to summarize specialty pharmacy fall short.

High drug prices are taking a toll not only on consumers’ wallets but on their health.

Matthew Hughes, director of Business Development for the Accreditation Commission for Health Care (ACHC), discusses how the accreditation process carries benefits for stakeholders across the specialty pharmacy space.

If a governmental agency and/or a PBM nevertheless concludes that the arrangement is “gaming the system,” then the agency/PBM will likely be motivated to bring the arrangement to an end.

Specialty drugs with limited distribution networks require pharmacies to put together an extensive request for proposal to gain access.

John Giannouris, vice president, Specialty Pharmacy Services, ValueCentric, discusses data collection and analytics services that aggregators can offer manufacturers.

As the 2018 midterm elections approach and the 115th Congress draws to a close, it is important for pharmacists to stay informed on legislative and regulatory issues that have the potential to affect their practice.

Joy Gilbert, Vice President, Operations, US Bioservices, a part of AmerisourceBergen, goes into detail about how pharmacies can engage specialty-naive prescribers.

Top news of the day from across the health care landscape.

Data revealed at ASCO shows combination of atezolizumab (Tecentriq), bevacizumab (Avastin), carboplatin, and paclitaxel reduced the risk of death by 22% compared with bevacizumab and chemotherapy.

In a study presented at ASCO, Cemiplimab shows substantial activity and durable responses with an acceptable safety profile in treatment of metastatic cutaneous squamous cell carcinoma.

Pegilodecakin (AM0010) with nivolumab (Opdivo) or pembrolizumab (Keytruda) induced an overall response rate in 41% in patients with advanced non–small cell lung cancer, according to findings presented at the 2018 ASCO Annual meeting.

Top news of the day from across the health care landscape.

Medication nonadherence in the United States reportedly costs the health care system $300 billion annually, but is this figure accurate?

Moxetumomab pasudotox is a nonchemotherapeutic drug that could become the standard of care for patients with relapsed/refractory hairy cell leukemia.

Luis Torres, MBA, Vice President, Managed Care, BioPlus Specialty Pharmacy, talks about popular strategies employers use to control drug spending.